Oral upadacitinib may be a promising treatment option for patients with atopic dermatitis-type chronic hand eczema that is uncontrolled by topical therapies, according to a study published in the Journal of Drugs in Dermatology.“One of the major stories of dermatology during the last 2 years has been the incredible education that has been done around [chronic hand eczema (CHE)],”